Hormonal
Elevated baseline serum levels of tyrosine and branched-chain/aromatic amino acids are strongly associated with a higher risk of incident type 2 diabetes in South Asian men, independent of obesity and insulin resistance measures.
For South Asian men, having higher levels of certain amino acids (like tyrosine and branched-chain amino acids) is a strong indicator of increased diabetes risk, even if you are not obese or insulin resistant. This suggests that metabolic health assessments should go beyond standard obesity measures. Regular monitoring of these markers, alongside lifestyle interventions focused on diet and physical activity, may help in early detection and prevention of type 2 diabetes.
Tyrosine was a particularly strong predictor of incident diabetes in South Asian individuals, even after adjustment for metabolic risk factors, including obesity and insulin resistance (adjusted OR for a 1 SD increment, 1.47, 95% CI 1.17,1.85, p=0.001) compared with Europeans (OR 1.10, 0.87, 1.39, p=0.4; p=0.045 for ethnicity×tyrosine interaction).
Why this rating
Prospective cohort study with 19-year follow-up, large sample size (n=1,279 European, n=1,007 South Asian), and rigorous adjustment for confounders.
Source
Diabetes risk and amino acid profiles: cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study
Therese Tillin et al. · Diabetologia · 2015
DOI 10.1007/s00125-015-3517-8
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →